Rucaparib clinical trials
Rucaparib is named as an intervention in 5 current clinical trials in our Israel, USA, Germany, Spain, Italy, Belgium, Denmark, Poland, Czechia, Japan, South Korea, Australia, Ireland, UK, China, France, Netherlands, Sweden, Turkey, Canada, Brazil, Mexico, Taiwan, Switzerland, Austria, Norway, Portugal and Singapore registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Bristol-Myers Squibb (1). The most-studied condition is Cancer.
Where Rucaparib is approved
All regulators →Of the three regulators tracked here, the first to approve Rucaparib was the EU, on 23 May 2018.
- 1 EU orphan designation, most recently for treatment of ovarian cancer (10 Oct 2012, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Rucaparib works
All drug targets →- PARP 1, 2 and 3 inhibitor InhibitorTarget: PARP 1, 2 and 3✓ In ChEMBL and the Guide to Pharmacology
- CancerPhase 3
- Fallopian tube cancerPhase 3
- Primary peritoneal carcinomaPhase 3
- Prostate cancerPhase 3
- Biliary tract cancerPhase 2
- Breast cancerPhase 2
- Cervical cancerPhase 2
- Endometrial cancerPhase 2
- Endometrial carcinomaPhase 2
- Exocrine pancreatic carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1173055, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7736, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Rucaparib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Rucaparib. 3 are current, and 2 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy NICE TA1055 | Optimised | 16 Apr 2025 | Current |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA1007 | Recommended | 17 Sep 2024 | Current |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA611 | Recommended (Cancer Drugs Fund) | 13 Nov 2019 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Rucaparib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- EUEuropean Union: RubracaEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Rucaparib
- ATC code
- L01XX55
- ChEMBL
- CHEMBL1173055
- DrugBank
- DB12332
- PubChem CID
- 9931954
- CAS number
- 283173-50-2
- FDA UNII
- 8237F3U7EH
- Wikidata
- Q7376558
- Wikipedia
- Rucaparib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Rucaparib
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Rucaparib
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 1 |
| pharmaand GmbH | 1 |
| Hoffmann-La Roche | 1 |
| The Netherlands Cancer Institute | 1 |
| Dana-Farber Cancer Institute | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rucaparib trials
How many clinical trials are testing Rucaparib?
5 current trials in our Israel, USA, Germany, Spain, Italy, Belgium, Denmark, Poland, Czechia, Japan, South Korea, Australia, Ireland, UK, China, France, Netherlands, Sweden, Turkey, Canada, Brazil, Mexico, Taiwan, Switzerland, Austria, Norway, Portugal and Singapore registers name Rucaparib (also registered as CO-338) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Rucaparib trials recruiting patients?
Yes. 2 of the 5 trials are recruiting: 1 with sites in Israel, 1 with sites in USA, 1 with sites in Germany, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Australia, 1 with sites in Ireland, 1 with sites in UK, 1 with sites in China, 1 with sites in France, 2 with sites in Netherlands, 1 with sites in Sweden, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Taiwan, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Norway and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rucaparib clinical trials?
Bristol-Myers Squibb (1), pharmaand GmbH (1), Hoffmann-La Roche (1) and The Netherlands Cancer Institute (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Rucaparib clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rucaparib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rucaparib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rucaparib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.